CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract

June 4, 2024

https://www.globenewswire.com/news-release/2024/06/04/2892919/25359/en/CytoSorbents-STAR-Registry-Data-on-Patients-on-Ticagrelor-Undergoing-CABG-Surgery-with-CytoSorb-Presented-at-EuroPCR-2024-Named-Top-Five-Finalist-for-Best-Scientific-Abstract.html

PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the recent data presentation entitled “Early CABG with Intraoperative Haemoadsorption in Patients on Ticagrelor: The Safe and Timely Antithrombotic Removal (STAR) Registry,” at the international EuroPCR 2024 conference in Paris, France – the world-leading course in interventional cardiovascular medicine with over 12,000 attendees – where it was also selected as a top 5 finalist in the best scientific abstract competition.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.